Clinical trials: Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy (CAA) is a condition caused by the build-up of a protein called amyloid, predominantly Aβ40, within the walls of brain blood vessels, especially those blood vessels in the occipital lobe of the brain.
- Trial name
- NCT01821118
- Testing
- Ponezumab
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 36 people
- Sponsor
- Pfizer